365 related articles for article (PubMed ID: 26086890)
1. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation.
Winner JG; Carhart JM; Altar CA; Goldfarb S; Allen JD; Lavezzari G; Parsons KK; Marshak AG; Garavaglia S; Dechairo BM
Curr Med Res Opin; 2015; 31(9):1633-43. PubMed ID: 26086890
[TBL] [Abstract][Full Text] [Related]
2. Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients.
Jablonski MR; Lorenz R; Li J; Dechairo BM
J Geriatr Psychiatry Neurol; 2020 Nov; 33(6):324-332. PubMed ID: 31842673
[TBL] [Abstract][Full Text] [Related]
3. Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care Setting.
Brown LC; Lorenz RA; Li J; Dechairo BM
Clin Ther; 2017 Mar; 39(3):592-602.e1. PubMed ID: 28238356
[TBL] [Abstract][Full Text] [Related]
4. Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications.
Tanner JA; Brown LC; Yu K; Li J; Dechairo BM
Clinicoecon Outcomes Res; 2019; 11():779-787. PubMed ID: 31849503
[TBL] [Abstract][Full Text] [Related]
5. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders.
Benitez J; Cool CL; Scotti DJ
Per Med; 2018 Nov; 15(6):481-494. PubMed ID: 30256179
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings.
Fagerness J; Fonseca E; Hess GP; Scott R; Gardner KR; Koffler M; Fava M; Perlis R; Brennan FX; Lombard J
Am J Manag Care; 2014 May; 20(5):e146-56. PubMed ID: 25326929
[TBL] [Abstract][Full Text] [Related]
7. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients.
Hornberger J; Li Q; Quinn B
Am J Manag Care; 2015 Jun; 21(6):e357-65. PubMed ID: 26247576
[TBL] [Abstract][Full Text] [Related]
9. Analysis of a panel-based pharmacogenomics testing program among members of a commercial and Medicare client of a pharmacy benefits manager.
Steinbach M; Wickizer M; Siwak A; Patel T; Olson J; Horowitz S; Topp R
J Manag Care Spec Pharm; 2022 Apr; 28(4):485-490. PubMed ID: 35332788
[No Abstract] [Full Text] [Related]
10. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM
BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
12. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs.
Rosenheck R; Leslie D; Sernyak M
Med Care; 2001 Mar; 39(3):302-8. PubMed ID: 11242324
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.
Winner JG; Carhart JM; Altar CA; Allen JD; Dechairo BM
Discov Med; 2013 Nov; 16(89):219-27. PubMed ID: 24229738
[TBL] [Abstract][Full Text] [Related]
14. Pharmacy performance while providing continuous medication monitoring.
Doucette WR; McDonough RP; Herald F; Goedken A; Funk J; Deninger MJ
J Am Pharm Assoc (2003); 2017; 57(6):692-697. PubMed ID: 28844583
[TBL] [Abstract][Full Text] [Related]
15. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.
Tsermpini EE; Skokou M; Ferentinos P; Georgila E; Gourzis P; Assimakopoulos K; Patrinos GP;
Psychiatriki; 2020; 31(4):341-351. PubMed ID: 33361064
[TBL] [Abstract][Full Text] [Related]
16. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
Hess GP; Fonseca E; Scott R; Fagerness J
Genet Res (Camb); 2015 Jun; 97():e13. PubMed ID: 26030725
[TBL] [Abstract][Full Text] [Related]
18. Optimizing medication use with a pharmacist-provided comprehensive medication management service for patients with psychiatric disorders.
Cobb CD
Pharmacotherapy; 2014 Dec; 34(12):1336-40. PubMed ID: 25329409
[TBL] [Abstract][Full Text] [Related]
19. Effects of antipsychotic medication on psychiatric service utilization and cost.
Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
[TBL] [Abstract][Full Text] [Related]
20. Implementation of a pharmacogenomics service in a community pharmacy.
Ferreri SP; Greco AJ; Michaels NM; O'Connor SK; Chater RW; Viera AJ; Faruki H; McLeod HL; Roederer MW
J Am Pharm Assoc (2003); 2014; 54(2):172-80. PubMed ID: 24632932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
